Check out our deep dive in MSI-H gastric cancer, now out in @CD_AACR . Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer https://t.co/2BgSrhKI80
New work with @JeeyunM@AnMinae exploring progressive changes in dysplasia to early gastric cancer. @SU2C@SU2Cscience
Genomic and Transcriptomic Changes in Early Gastric Cancer Inform Clinical Risk Stratification Prior to Endoscopic Resection https://t.co/eHPsoF5BHK
Adding to the literate on this macrophage subset in checkpoint response. @jitcancer@JeeyunM@AnMinae@MassGenBrigham
Spatially resolved SPP1 expression is a biomarker of chemoimmunotherapy efficacy in advanced gastric cancer https://t.co/Xus8O3r9eQ
🚨Positive Phase III trial in #GastricCancer
💊TroFuse015: sacituzumab tirumotecan (TROP2 ADC)
📊Significant OS benefit in 3L+ gastroesophageal cancer (n=473)
⚠️PFS not met but first TROP2 ADC with OS benefit
@KoheiShitara@YJanjigianMD@KlempnerSam
https://t.co/JuMySXDGEi
Just published in @CCR_AACR https://t.co/UCnPI1PbQe
We describe the role of Claudin18.2 and components of the TME such as B-cells as predictors of response to treatment and cancer progression in gastroesophageal cancer @josephjzhao@KlempnerSam@sm_blum@choong_kun@YJanjigianMD
CLARITY- Gastric 01 (CG-01) Phase III AZD-0901 (Sone-Ve) in 2L+ met #Claudin 18.2 (+) in #Gastroesophageal#cancer vs. investigators choice (N=594)
Primary endpoints: PFS + OS
🔹OS: 10M vs. 5M (HR = 0.47) 👏
🔹12M OS: 38.1% vs. 18.1%, HR = 0.47 (3rd line)
🔹 12M 42.6% in 2nd line
🔹 ORR: 23.3% vs. 13.8%
🔹PFS: HR = 0.77 was NS in 2L+
🔹PFS: HR = 4.1 vs. 2.7M; HR = 0.56 in 3L+
🔹Need more data in the 2L setting; largest benefit seen in 3L+ setting
#ESMO2026 @OncoAlert #cancerresearch @AstraZeneca
📢FDA approval of zanidatamab + chemotherapy ± tislelizumab in the 1L setting represents an important advance and ushers in a new era for HER2-directed therapy in GEA.
Congratulations to the investigators, patients, and teams who made this possible! #GastricCancer#HER2#GIOnc
Always fun to write with @sundar__raghav. In @MedCellPress. Reprogramming HER2-Positive gastroesophageal cancer immune contexture with bispecific therapy: HERIZON-GEA-01: Med https://t.co/XAmm22wNn2
Now online @CellRepMed and led by talented grad student Sam Wright. Team effort with @JeeyunM@AnMinae@arnavmehta3@getz_lab and Ryan Park lab.
We examine T cell clonal dynamics during frontline chemoimmunotherapy in advanced gastric cancer
https://t.co/nId7WpanbX
In the @NEJM, hidden in the #ASCO26 flurry, is our letter highlighting response to first-in class approach to directly targeting beta-catenin:TCF interaction
Targeting of Wnt–β-Catenin Pathway in Recurrent Ameloblastoma | New England Journal of Medicine https://t.co/4FLXo5Gzlg
Thrilled to share phase 3 HERIZON-GEA-01 in @NEJM before @ASCO. Biparatopic anti-HER2 Zanidatamab plus chemo±tislelizumab improved PFS in HER2+ gastric/GEJ cancer; the tislelizumab combo also improved OS. Grateful to all patients and collaborators.
https://t.co/fhMUH2uO3L
Now out online in @Cancer_Cell . Fun writing this with @sundar__raghav and talented student Luke Tillman and other.
Reimagining HER2 therapy: Bridging oncogene addiction and immune modulation: Cancer Cell https://t.co/HNRkawoJYz
Delighted to share results of phase 2 ILUSTRO in @NatureMedicine@KlempnerSam@ASCOPost Zolbetuximab+FOLFOX+nivo showed encouraging activity in CLDN18.2+ gastric cancer with mPFS 14.8 months (18months in high CLDN). Supporting the ongoing phase 3 LUCERNA.
https://t.co/KQZzsNRlB6
How low can you go? Looking at broader CLDN18.2 cutoffs in GC/GEJ. Nice work from visiting researcher from Korea, courtesy of @JeeyunM@myESMO
https://t.co/d44QHiOdlx